Supplement: https://doi.org/10.3126/jpahs.v8i3.42030

		Selec	rtion		Comparability		Outcome		
Study	<i>Representativeness</i> of <i>Exposed</i> Cohort	Selection of Non exposed	Ascertainment of Exposure	Outcome Not Present at Start Of study	Comparability of cohorts	Assessment of Outcome	Adequate Follow- Up Length	Adequacy of Follow- Up	Overall
Zhang X ¹⁷	1	1	1	1	1	1	1	1	8
Wu Chaomin ²⁰	1	1	1	1	2	0	1	1	8
Wang Z ¹⁹	1	1	1	1	1	0	1	1	7
Wang D^{11}	1	1	1	1	1	1	1	1	8
Wan S ²⁴	1	1	1	1	1	1	1	1	8
Chen G ²⁵	1	1	1	1	1	0	1	1	7
Rong Qu ²⁶	0	1	0	1	1	0	1	1	5
Gao Yong ²⁷	1	1	1	1	1	0	1	1	7
Qian Guo- Qing ²⁸	0	1	1	1	1	0	1	1	6
Liu Wei ¹⁸	1	1	1	1	1	0	1	1	8
Zhang Guqin ²⁹	1	1	1	1	2	1	1	1	9
Hansheng Xie ³⁰	1	1	1	1	2	1	1	1	9
Zheng Meijuan ³¹	1	1	1	1	1	0	1	1	7
Guan W ⁹	1	1	1	1	1	1	1	1	8
Huang Rui ³²	1	1	1	1	1	1	1	1	8

Supplementary Table 1: Newcastle-Ottawa quality assessment scale

Supplement								Si	upplement
Zhao Xin-	1	1	1	1	2	1	1	1	9
Ying ³⁴									
Hajifathalian	1	1	1	1	2	1	0	0	7
Kaveh ¹⁶									
Cai	1	1	1	1	2	1	1	1	9
Qingxian ¹⁰									
Fan Zhenyu ¹²	1	1	1	1	2	1	1	1	9
Xiaolong Qi ³³	1	1	1	1	1	1	1	1	8
Fei Zhou ³⁵	1	1	1	1	2	1	1	1	8
Yang X ³⁶	1	1	1	1	1	0	1	1	8
Qiurong	1	1	1	1	1	1	1	1	8
Ruan ³⁷									
Chen T ³⁸	1	1	1	1	2	1	1	1	9
Du Rong-	1	1	1	1	1	1	1	1	8
Hui ³⁹									
Lang Wang ⁴⁰	1	1	1	1	1	0	1	1	7
TieLong	1	1	1	1	1	1	1	1	8
Chen ⁴¹									
Haiying Sun ⁴³	1	1	1	1	2	0	1	1	8
Deng Y ⁴²	1	1	1	1	2	0	1	1	8
Moon	1	1	1	1	1	1	1	1	8
Xiaolong Qi 2	1	1	1	1	2	1	1	1	9
Wang Yijin	1	1	1	1	2	1	1	1	9

Supplementary Table 2a: Study characteristics included in meta-analysis

Study	Country	Study Period	Study type	Total N	Arms	n	S	ex	Age (yrs)	COVID-19 diagnosis
							Μ	F		
Zhang X ¹⁷	China	Jan 17 to Feb	Retrospective	645	Mild	72	33	39	45.33±47.42	Real-time RT-
-		8, 2020	_		Severe	573	295	278		PCR
Wu Chaomin ²⁰	China	Dec 25,	Retrospective	201	Mild	117	68	49	51±2.83	Real-time RT-
		2019, to Jan 26, 2020			Severe	84	60	24		PCR
Wang Z ¹⁹	China	Ja n	Retrospective	69	Mild	55	25	30	42.0±6.75	Real-time RT-
		16 to Jan 29, 2020			Severe	14	7	7		PCR
Wang D ¹¹	China	Jan 1 to	Retrospective	138	Mild	102	53	49	56±4.33	Real-time RT-
		Jan 28, 2020			Severe	36	22	14		PCR
Wan S ²⁴	China	Jan 23 to Feb	Retrospective	135	Mild	95	52	43	47±3.16	Real-time RT-
		8, 2020			Severe	40	21	19		PCR
Chen G ²⁵	China	Dec 19, 2019	Retrospective	21	Mild	11	7	4	56.3±14.3	Real-time RT-
		to Jan 27, 2020			Severe	10	10	0		PCR
Rong Qu ²⁶	China	Jan 2020 to	Retrospective	30	Mild	27	16	14	50.5 ± 28.28	Real-time RT-
		Feb 2020			Severe	3				PCR
Gao Yong ²⁷	China	Jan 23, 2020 to Feb 2,	Retrospective	43	Mild	28	17	11	43.74±36.12	Real-time RT- PCR
		2020			Severe	15	9	6		I CK
Qian Guo-Qing ²⁸	China	Jan 25 to 11	Retrospective	91	Mild	82	37	54	50±3.41	Real-time RT-
		Feb 2020			Severe	9				PCR
Liu Wei ¹⁸	China	Dec 30,	Prospective	78	Mild	67	32	35	38±4	Real-time RT-
		2019, to Jan 15, 2020			Severe	11	7	4		PCR
Zhang Guqin ²⁹	China		Retrospective	221	Mild	166	73	93	55.0±4.58	

		Jan 2, 2020 to Feb 10, 2020			Severe	55	35	20		Real-time RT- PCR
Hansheng Xie ³⁰	China	Feb 2, 2020 to Feb 23, 2020	Retrospective	79	Mild Severe	51 28	26 18	25 10	60.0±3	Real-time RT- PCR
Zheng Meijuan ³¹	China	NA	Retrospective	68	Mild Severe	55 13	26 10	29 3	47.13±11.84	Real-time RT- PCR
Guan W ⁹	China	Dec 11, 2019, to Jan	Retrospective	1099	Mild	926	540	386	47.0±3.83	Real-time RT- PCR
		29, 2020			Severe	173	100	73		
Huang Rui ³²	China	Jan 22, 2020	Retrospective		Mild	179	99	80	44.0±3.5	Real-time RT-
		to Feb 10, 2020		202	Severe	23	16	6		PCR
Zhao Xin-Ying ³⁴	China	Jan 16, 2020 to Feb 10,	Retrospective	91	Mild	61	35	26	46	Real-time RT- PCR
		2020			Severe	30	14	16		
Hajifathalian Kaveh ¹⁶	USA	March 4 to April 9,	Retrospective	1059	Mild	291	145	146	61.1±18.3	Real-time RT- PCR
		2020			Severe	768	466	302		
Cai Qingxian ¹⁰	China	Jan 11, 2020 to	Retrospective	417	Mild	326	NA	NA	47±4.3	Real-time RT- PCR
		Feb 21, 2020			Severe	97	NA	NA		
Fan Zhenyu ¹²	China	Jan 20, 2020 to Jan 31,	Retrospective	148	Liver Injury	55	41	14	50±4.67	Real-time RT- PCR
		2020			Without Liver Injury	93	32	61		
Xiaolong Qi ³³	China		Retrospective	70	Liver Injury	32	23	9	41±5.6	

		Jan 23, 2020 to Feb 18, 2020			Without Liver Injury	38	16	22		Real-time RT- PCR
Fei Zhou ³⁵	China	Dec 29, 2019 to Jan 31, 2020	Retrospective	191	Survivor	137	81	56	56.25±6	Real-time RT- PCR
					Non-survivor	54	38	16		
Yang X ³⁶	China	Dec 24,	Retrospective	52	Survivor	20	14	6	59·7±13·3	Real-time RT
		2019, to Jan 26, 2020			Non-survivor	32	21	11		PCR
Qiurong Ruan ³⁷	China		Retrospective	150	Survivor	82	53	29	57.7±51.36	Real-time RT-
					Non-survivor	68	49	19		PCR
Chen T ³⁸	China	Jan 13 to 12	Retrospective	274	Survivor	161	88	73	59.5±7.48	Real-time RT-
		Feb 2020			Non-survivor	113	83	30		PCR
Du Rong-Hui ³⁹	China	Dec 25, 2019	Retrospective	179	Survivor	158	87	71	57.6±13.7	Real-time RT-
		to Feb , 2020			Non-survivor	21	10	11		PCR
Lang Wang ⁴⁰	China	Jan 1 to Feb	Retrospective	339	Survivor	274	127	147	69.75±3.17	Real-time RT-
		6			Non-survivor	65	39	26		PCR
TieLong Chen ⁴¹	China	Jan 1, 2020,	Retrospective	55	Survivor	36	18	18	76±7.51	Real-time RT-
		to Feb 10, 2020			Non-survivor	19	16	3		PCR
Haiying Sun ⁴³	China	Jan 1, 2020	Retrospective	244	Survivor	123	51	72	69.4±6.9	Real-time RT-
		to Feb 21, 2020			Non-survivor	121	82	39		PCR
Deng Y ⁴²	China	Jan 1, 2020	Retrospective	215	Survivor	116	51	65	54±5.2	Real-time RT-
		to Feb 21, 2020			Non-survivor	109	73	36		PCR
Moon	UK	March 25,	Retrospective	152	Survivor	105	61	44	61±3.83	Real-time RT-
		2020 to			Non-survivor	47	30	17		PCR

		April 20, 2020								
Xiaolong Qi 2	China	Dec 31, 2019	Retrospective	21	Survivor	16	7	9	64.5±4	Real-time RT-
		to March 24, 2020			Non-survivor	5	11	6		PCR
Wang Yijin	China	Jan 20, 2020	Retrospective	156	Liver Injury	64	38	26	51.15±49.50	Real-time RT-
		to			Without Liver	92	44	48		PCR
		March 25, 2020			Injury					

Supplementary Table 2b: Study characteristics included in meta-analysis (Liver function. Abnormal Liver function tests, Liver Injury and gastrointestinal complications)

Study	Total (N)	CLD	Liver F	Function			Abdor	ninal Syı	mptoms		Treatment	Comments
			Value(M±SD	Abnormal LFTs %	Liver Injury %	Diarrhoea n(%)		Vomiti ng n(%)	Abdomin al Pain n(%)	Anorexia n(%)		
Zhang X ¹⁷	645	25	ALT- 28.94±38.25 AST- 29.58±35.57 TBil- 11.02±13.45 INR-1.03±1.03 Albumin-41.18 LDH-208.7±208.89	NA	12.5%	53	22	NA	NA	NA	Anti- coronavirus treatment, Glucocorticoid s, Oxygen therapy, Mechanical ventilation	Clinical features and radiograph score in COVID-19 patients can effectively predict severe/critical type.

Wu Chaomin ₂₀	201	7	ALT- 31±4.52 AST- 33±3.16 TBil- 11.45±0.95 Prothrombin Time- 11.1±0.28	ALT- 21.71% AST- 29.79% TBil- 5.05% PT- 2.07% Albumin- 98.48% LDH- 97.97%	NA	NA	NA	NA	NA	NA	Oxygen Therapy, Empirical Antibiotic, Antiviral (oseltamivir ganciclovir, lopinavir/riton avir, interferon alfa), antioxidant therapy, Methylpre nisolone, immunom dulators (immunoglobu lin, thymosin, and recombine t human granulocyte colony	• 1
											colony stimulating factor)	
Wang Z ¹⁹	69	1	ALT- 25±5.75 AST- 24±6 LDH- 224±27	ALT- 33.33% AST- 27.53% LDH- 40.9%	NA	10(14%)	3(4%)	NA	NA	7(10%)	Oxygen support, Antibiotics (moxifoxacin treatment) and Antiviral therapy (interferon	Older patients or those with underlying comorbidities are at higher risk of death.

Wang D ¹¹	138	NA	ALT- 24±4 AST- 31±4.5 TBil 9.8±0.95 Prothrombin- 13±0.23	NA	NA	14 (10.1%)	14 (10.1%)	5 (3.6%)	3 (2.2%)	NA	therapy), antifungal drugs, corticosteroids Antiviral therapy, Glucocorticoid therapy, Oxygen	Hospital- related transmission of 2019-nCoV was suspected
			LDH-261±36.83								inhalation, CRRT, ECMO	1 /
Wan S ²⁴	95	2	ALT-26±3.37 AST- 33.4±2.65 TBil 8.6±1.3 Prothrombin Time- 10.9±0.15 Albumin- 40.5±1.06 LDH- 320.5±18.3	AST- 22.22% LDH- 42.96%	NA	18 (13.3%)	NA	NA	NA	NA	Oxygen support, Antiviral therapy, Antibiotic therapy, corticosteroid, Traditional Chinese medicine, CRRT,	patients
Chen G ²⁵	21	NA	ALT- 30±16.5 AST- 38.2±24.6 TBil. 9.8±5.6 Prothrombin Time- 13.8±1.0 Albumin-34.4±5.7 LDH- 408.1±231	AST- 28.6%	4.76%	NA	NA	NA	NA	NA	Oxygen Therapy, Antiviral therapy (oseltamivir and ganciclovir), ECMO, antimicrobial treatment	SARS-CoV-2 infection may affect primarily T lymphocytes, especially CD4+T cells, resulting in significant decrease in

											(moxifloxacin or cefoperazone- sulbactam), corticosteroids (methylpredni solone)	number as well as IFN-γ production, which may be associated with disease severity.
Rong Qu ²⁶	30	NA	ALT- 35.73±40.86 AST- 45.13±47.04 LDH- 745.07±798.84	NA	NA	NA	NA	NA	NA	NA	Hormones, Supportive treatments	Patient with markedly elevated platelets and longer average hospitalization days may be related to the cytokine storm.
Gao Yong ²⁷	43	NA	ALT- 28.4±30.81 AST- 26.72±27.08 PT- 11.34±11.36	NA	NA	NA	NA	NA	NA	NA	NA	IL-6 and D- dimer levels can be used to estimate the severity of COVID-19
Qian Guo- Qing ²⁸	91	NA	ALT- 18.92±16.71 AST- 21.59±10.78 Albumin- 43±47.25	NA	NA	NA	NA	6(6.59 %)	NA	23(25.27 %)	NA	Early diagnosis, early isolation and early management all contributed to reducing transmission and mortality

Liu Wei ¹⁸ Zhang Guqin ²⁹	78	NA 7	ALT- 18.1±2.83 AST-20.5±3.28 Albumin-40.47±5.21 ALT-23±3.83 AST-29±4.5 TBil- 10±1.03 PT- 12.9±0.25 LDH-227±32.16	NA	NA	NA 25 (11.3%)	NA	NA	NA 5 (2.3%)	NA 80 (36.2%)	lopinavir Cephalosporin s, quinolone, Glucocorticoid s, gamma globulin, thymosins, Oxygen Therapy, Antiviral therapy, Glucocorticoid , CRRT,	smoking, maximum body temperature at admission, respiratory failure, albumin, and C-reactive protein led to the progression of COVID-19 Covid-19 patients with older age and chronic comorbidities, developed
Hanshen	79	NA	ALT- 34±8.16	NA	36.70%	7(8.9%)	NA	NA	NA	NA	ECMO	more than one complication. The close
g Xie ³⁰	19		AL1- 34±8.16 AST- 30±4.5 GGT- 31.5±10.38 TBil- 13.61±1.46	INA	50.70%	/(8.9%)	INA			INA	INA	and evaluation of liver function in

												COVID-19 patients with severe pulmonary imaging lesions should be considered.
Zheng Meijuan ³	68	NA	ALT- 24.17±19.75 AST- 14.92±10.77 TBil- 14.927(4.7- 47.8) PT- 11.713(9.7- 17.7)	NA	NA	3/68(4.41%)	55	NA	NA	NA	Oxygen Therapy, Hydroxychlor oquine/ Chloroquine, Interferon therapy, Antibiotic therapy,	Targeting NKG2A may prevent the functional exhaustion of cytotoxic lymphocytes and consequently contribute to virus elimination in the early stage of SRAS- CoV-2 infection.
Guan W ⁹	1099	NA	NA	ALT: 21.32% AST- 22.19% TBil- 10.52% LDH- 41.03%	NA	42	55	NA	NA	NA	Oxygen therapy, Antibiotics, Antiviral, Corticosteroid s, Intravenous immunoglobin , ECMO.	U

												complicated the diagnosis and hence cause rapid spread.
Huang Rui ³²	202	4	ALT- 25±2.66 TBil- 9.9±1.16 PT - 12.8±0.23 LDH-236.5±32.41	NA	NA	13	NA	4	NA	NA	therapy (Atomized	A BMI > 28 kg/m2 and a history of type 2 diabetes are independent risk factors for severe illness of COVID-19

Zhao	91	NA	NA	ALT-	19.7%	14	11	NA	2	11	Oxygen	Besides
Xin-				12.01%							therapy,	respiratory
Ying ³⁴				AST-								problem, liver,
				19.78%							(cephalospori,	kidney,
				PT- 20.87%							fluoroquinolon	digestive tract,
											es,	and heart
											carbapenems),	injuries are
											Immunoglobul	common in
											in, antiviral	COVID-19
											therapy	patients.
											(oseltamivir,	
											lopinavir/riton	
											avir,	
											umifenovir),	
											glucocorticoid	
Hajifatha	1059	32	ALT- 49.5±64.9	NA	NA	234	168	91	72	240	NA	In COVID-19
lian			AST-59.5±78.5									patients liver
Kaveh ¹⁶			TBil-11.97±10.26									injury is
			INR-1.3±0.8									commonly
			Albumin-33±6									seen on initial
												presentation,
												and is
												independently
												associated
												with poor
												clinical
												outcomes

Cai	417	21	ALT- 46±8.16	AST-	21.5%	NA	NA	NA	NA	NA	Antibiotics,	Patients with
Qingxian		21	AST-38±4	58.80%	21.370	INA	INA	INΛ	INA		NSAIDs,Ribav	
			GGT-47.5±9.16	AST-							irin,	tests had
			TBil- 20±2.16	47.16%							Oseltamivir,	significantly
			1 DII- 20±2.10	47.10% GGT-							Herbal	higher odds of
				48.74%							medications,	
				48.74% TBil-							Interferon,	developing severe
				64.15%							,	
				04.13%							Lopinavir/rito	pneumonia.
											navir	Moreover,
												antiviral
												(lopinavir/rito
												navir) used in treatment for
												COVID-19
												increased the
												risk of liver
Fan	148	9	NA	NA	52%	6	3	NA	NA	NA	Companying	injury.
		9	NA	INA	52%	6	3	NA	NA	NA	Supportive	Patients with
Zhenyu ¹²											treatments like fluid	
												infection who
											electrolyte and	
											acid-base	Lopinavir/rito
											homeostasis,	navir have
											oxygen	abnormal liver
											therapy,	function, and
											Antiviral	this is
											therapy	associated
											(lopinavir/liton	0
											avir,	hospital stay.
											umifenovir	
											and	
											darunavir),	

											and antibiotics.	
Xiaolong Qi ³³	70	NA	NA	ALT- 21.43% AST- 7.14% TBil- 35.71%	45.7%	7	NA	NA	NA	NA	Antiviral treatment with interferon inhalation, lopinavir and ritonavir, combined with probiotics.	Dynamic monitoring the liver function of patients with liver injury is recommended as hospital stay of patient with liver injury is not statically different that of without liver injury.
Fei Zhou ³⁵	191	NA	ALT- 30·0± 4.83 PT- 11·6 ±0.4 LDH- 300·0±28.83 Albumin- 32·3± 1.11	AST- 31% PT- 6% LDH- 67%	NA	9 (5%)	NA	7 (4%)	NA	NA	Antiviral, Corticosteroid s, Intravenous immunoglobin , ECMO.	The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 µg/mL could help clinicians to identify patients with poor prognosis at an early stage.
Yang X ³⁶	52	NA	ALT- 59·7±13·3 TBil- 17.03±19.20	NA	28.8%	NA	NA	2 (4%)	NA	NA	Oxygen Therapy,	The survival time of

г — т												
			PT-12.13±11.8727								Antiviral,	The non-
											Antibacterial,	survivors is
											Glucocorticoid	~
											s,	within 1–2
											Immunoglobul	
											in,	ICU
											Vasoconstricti	
											ve agents,	Older patients
											CRRT, ECMO	• • •
												with
												comorbidities
												and ARDS are
												at increased
	1.50		4 T (T)				3.7.4					risk of death.
Qiu Rong	150	4	ALT-	NA	NA	NA	NA	NA	NA	NA	NA	The predictors
Ruan ³⁷			104.04±678.08									of a fatal
			AST-									outcome in
			153.21±1273.5									COVID-19
			TBil- 15.2±16.34									cases included
			Albumin-									age, the
			30.93±25.68 LDH-									presence of
			573.48±1867.55									underlying
			3/3.46±180/.33									diseases, the presence
												of secondary
												infection and
												elevated
												inflammatory
												indicators in
												the blood.
Chen T ³⁸	274	15	ALT- 23±3.83	ALT- 22%	4.7%	77 (28%)	74(9%)	16 (6%)	19 (7%)	66 (24%)	Oxygen	Acute
	214	15	AST- 30±4	ALT- 22% AST- 31%	т.//0	11 (2070)	עד (י∕ע)	10 (0/0)	17(770)	00(24/0)	treatment,	respiratory
				1101-31/0							treatment,	respiratory

			GGT- 33±5 TBil- 9.6±1.13 PT- 14.3±0.33 Albumin- 33.9±1.21 LDH- 321.5±43.45	Albumin- 35% LDH- 42%							Antiviral therapy, Glucocorticoid therapy, Antibiotics, Intravenous immunoglobul	distress syndrome and respiratory failure, sepsis, acute cardiac injury, and heart failure
											in, Interferon inhalation, CRRT, ECMO	were the most common critical complications during exacerbation of covid-19.
Du Rong- Hui ³⁹	179	21	ALT- 22±4.16 AST- 30±4 GGT- 29±5.91 TBil- 8.9±0.98 PT- 13.7±0.5 Albumin- 33.2±0.95	NA	NA	39 (21.8%)	NA	NA	NA	NA	Oxygen therapy,antibio tics, antiviral drug,glucocort icoids,γ- globulin,mech anical ventilation	Four risk factors, age \geq 65 years,

												predictors for mortality of COVID-19 patients.
Lang Wang ⁴⁰	339	2	ALT- 27±4.5 AST- 32±3.83 PT- 12.1±0.18 LDH- 301±34.16	NA	28.3%	43 (12.7%)	13 (3.8%)	NA	NA	94 (27.8%)	NA	Rapid disease progress was noted in the dead with a median survival time of 5 days after admission. Dyspnea, lymphocytope nia, comorbidities including cardiovascular disease and chroni obstructive pulmonary disease, and acute respiratory distress syndrome were predictive of poor outcome
TieLong Chen ⁴¹	55	NA	ALT- 41.3±67.75 AST- 63.1±47.75	NA	NA	4	NA	4	4	5	Antiviral (arbidol,	Patients aged 65 and older

			Albumin- 33.3±4.5								interferon-	had greater
			LDH- 395±155.5								alpha	initial
											inhalation,	comorbidities,
											lopinavir and	more severe
											ritonavir),	symptoms,
												and were more
											, gamma	likely to
											globulin,	experience
											Quinolones	multi-organ
											and second-	involvement
											generation	and death.
											beta-lactams	
Haiying	244	NA	ALT- 24.97±22.93	NA	NA	72	NA	NA	10	NA	Antiviral	Older age and
Sun ⁴³			AST- 36.43±35.01								drugs,	lower
											glucocorticoid	lymphocyte
											and traditional	count on
											Chinese	admission
											medicine	were
												associated
												with death in
												hospitalized
												COVID-19
												patients.
												Stringent
												monitoring
												and early
												intervention
												are needed to
												reduce
												mortality in
												these patients.


Deng Y ⁴²	215	NA	ALT- 25.04±22.53 AST- 27.18±27.01	NA	NA	33	NA	NA	NA	NA	Intravenous corticosteroids , intravenous gammaglobuli n (IVIG), antiviral	Non+survivor patients had higher complications such as ARDS, acute
											drugs,antibioti cs, antifungal drugs,and respiratory supports	cardiac injury, acute kidney injury, shock, and DIC.
Moon	152	21	TBil- 18.81±3.7 PT- 13±0.01 Albumin- 34±9.33	NA	25.7%	NA	NA	NA	NA	NA	Chloroquine/h ydroxychloroq uine,Lopinovir /ritonavir,Tocil izumab,and Interferon- alpha	disease severity is
Xiaolong Qi 2	21	21	ALT- 30±5.5 AST- 39.5±7 GGT- 31.25±9.75 TBil- 15.52±2.97 PT- 13±0.7 Albumin- 33.47±2.92 LDH- 319.75±47.75	NA	4.8%	2	NA	NA	NA	NA	Antiviral treatment, Antibiotic treatment, Glucocorticoid s, Intravenous immunoglobul in	The cause of death in most patients was respiratory failure rather than progression of liver disease (ie, development of ACLF).

Supplement

Wang	156	NA	ALT- 31.71±29.13	NA	41%	18	5	NA	NA	NA	PEG-	Hepatic
Yijin			AST- 32.82±29.31								Interferon,	impairment in
			GGT- 31.43±29.22								Lopinavir/Rito	COVID-19
			TBil- 9.91±9.10								navir,	patients is
			PT-11.92±10.87								Antibiotic	caused by
			Albumin-								treatment	SARS-CoV-2
			36.94±34.44								Corticosteroid	infection of
			LDH-								Intravenous	the liver
			243.02±219.33								immunoglobul	
											in therapy	

ABBREVIATIONS: ALP- Alkaline phosphatase; ALT- Alanine aminotransferase; AST- Aspartate aminotransferase; GGT- Gammaglutamyltransferase; PT- Prothrombin time; TBil- Total bilirubin; LDH- Lactate dehydrogenase; ACLF- Acute-on-chronic liver failure Supplementary figure 1: Forest plot for COVID-19 patients with underlying chronic liver disease (CLD) in COVID-19 patients

Forest plot for pooled estimate of the prevalence of chronic liver disease in COVID-19 patients



Forest plot for prevalence of chronic liver disease in COVID-19 patients between mild and

severe group

	Milo	1	Seve	re		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Cai Qingxian	4	225	31	192	18.4%	0.09 [0.03, 0.27]	
Guan W	22	926	1	173	11.2%	4.19 [0.56, 31.26]	
Huang Rui	4	179	0	23	6.9%	1.21 [0.06, 23.10]	
Kaveh Hajifathalian	8	291	24	768	20.5%	0.88 [0.39, 1.97]	
Wan S	1	95	1	40	7.5%	0.41 [0.03, 6.80]	
Wang Z	1	55	0	14	6.0%	0.80 [0.03, 20.64]	
Zhang Guqin	3	166	4	55	14.5%	0.23 [0.05, 1.08]	
Zhang X	2	72	23	573	15.0%	0.68 [0.16, 2.96]	
Total (95% CI)		2009		1838	100.0%	0.53 [0.21, 1.33]	•
Total events	45		84				
Heterogeneity: Tau ² =	0.90; Chi	i ^z = 17.3	21, df = 7	(P = 0.	02); I ² = 5	9%	0.002 0.1 1 10 500
Test for overall effect:	Z = 1.36 ((P = 0.1	7)				0.002 0.1 1 10 500 Favours (Severe) Favours (Mild)


Forest plot for prevalence of chronic liver disease in COVID-19 patients between survivor

and non-survivor group


	Surviv	/or	Non-Surv	rivor		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Chen Tao	6	161	8	13	15.3%	0.02 [0.01, 0.10]	
Chen TieLong	1	36	1	19	11.7%	0.51 [0.03, 8.71]	
Hui Du Rong	19	158	6	21	16.0%	0.34 [0.12, 0.99]	
Moon	105	152	47	152	16.7%	4.99 [3.07, 8.12]	-
Qiurong Ruan	3	82	1	68	13.1%	2.54 [0.26, 25.04]	
Wang Lang	1	339	1	65	11.9%	0.19 [0.01, 3.07]	
Xiaolong Qi 2	16	21	5	21	15.2%	10.24 [2.47, 42.37]	
Total (95% CI)		949		359	100.0%	0.76 [0.13, 4.39]	
Total events	151		69				
Heterogeneity: Tau² = Test for overall effect:	•			P ≺ 0.0	0001); I²:	= 92%	0.001 0.1 1 10 1000 Favours [Non-Survivor] Favours [Survivor]

Supplementary figure 2: Forest plot for pooled results of liver function related indexes


Forest plot for pooled result ALT




Forest plot for pooled result of AST




Forest plot for pooled result of GGT




Forest plot for pooled result of TBil




Forest plot for pooled result of Albumin




Forest plot for pooled result of PT



Forest plot for pooled result of LDH




Forest plot for pooled result of ALP



Supplementary figure 3: Forest plot for pooled prevalence of abnormal liver function related

indexes


Forest plot for pooled prevalence of increased ALT




Forest plot for pooled prevalence of increased AST

Studies	Estin	nate (95	& C.I.)	Ev/Trt					
Wu Chaomin	0.298	(0.234,	0.362)	59/198					
Wang Z	0.275	(0.170,	0.381)	19/69	-			_	
Wan S	0.222	(0.152,	0.292)	30/135					
Guan W	0.222	(0.192,	0.252)	168/757					
Zhao Xin-Ying	0.198	(0.116,	0.280)	18/91					
Chen T	0.307	(0.252,	0.361)	84/274					
Cai Qingxian	0.472	(0.417,	0.527)	150/318					-
Overall (I^2=91% , P< 0.001)	0.286	(0.211,	0.361)	528/1842					
						0.2	0.3 Proportion	0.4	0.5


Forest plot for pooled prevalence of increased TBil




Forest plot for pooled prevalence of decreased Albumin



Forest plot for pooled prevalence of prolonged PT



Forest plot for pooled prevalence of increased LDH



Supplementary figure 4: Forest plot for age between patients with liver injury and patients without liver injury


	+ Liv	er Inju	ry	- Liv	er Inju	ry	9	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Cai Qingxian	53	5.5	85	47	4.66	223	21.2%	1.22 [0.95, 1.49]	
Fan Zhenyu	52	7	55	50	4.5	93	20.5%	0.36 [0.02, 0.69]	•
Hansheng Xie	62	5.25	29	56	4.89	50	18.7%	1.18 [0.69, 1.68]	+
Qi Xiaolong	41	5.6	32	38.5	5.31	38	18.9%	0.45 [-0.02, 0.93]	-
Wang Yijin	51.1	17.4	64	51.2	15.2	92	20.7%	-0.01 [-0.33, 0.31]	+
Total (95% CI)			265			496	100.0%	0.64 [0.12, 1.16]	◆
Heterogeneity: Tau ² = Test for overall effect	-			f= 4 (P ·	< 0.00	001); I²	= 90%		-10 -5 0 5 10 Favours [- Liver Injury] Favours [+ Liver Injury]


Supplementary figure 5: Forest plot for association between liver injury and gastrointestinal symptoms

	+ Liver I	njury	- Liver II	njury		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl	
Fan Zhenyu	2	55	7	93	21.5%	0.46 [0.09, 2.32]			
Hansheng Xie	2	29	4	50	11.7%	0.85 [0.15, 4.96]			
Qi Xiaolong	5	32	5	38	16.6%	1.22 [0.32, 4.67]			
Wang Yijin	7	64	16	92	50.2%	0.58 [0.23, 1.51]			
Total (95% CI)		180		273	100.0%	0.69 [0.37, 1.32]		-	
Total events	16		32						
Heterogeneity: Chi ² =	: 1.11, df=	3 (P = 0	.78); I ^z = 0)%			L		4.00
Test for overall effect	: Z=1.11 (P = 0.27	")				0.01 F	0.1 1 10 Favours (- Liver Injury) Favours (+ Liver	


Supplementary figure 6: Funnel Plot for Publication bias

A. Funnel Plot for severity of COVID-19 patients stratified according to liver injury







B. Funnel Plot for mortality of COVID-19 patients stratified according to liver injury



C. Funnel Plot for length of hospital stay of COVID-19 patients stratified according to liver injury



D. Funnel Plot for for the use of Lopinavir/ritonavir stratified according to liver injury



E. Funnel Plot for gastrointestinal symptoms stratified according to liver injury

Supplementary Table 4. Subgroup analysis of liver function and Liver injury in COVID-19.

4a. Pooled results of liver function related indexes in COVID-19 patients.

Factors	Pooled results
ALT level from 19 studies(1, 2, 10, 13, 14, 16, 19-26, 31-33, 35, 36)	28.53 U/L (95% CI: 26.90–30.98; I ² = 99%)
AST level from 17 studies(1, 2, 13, 14, 16, 19-25, 31-33, 35, 36)	30.53 U/L (95% CI: 28.47–32.59; I ² = 99%)
GGT level from 4 studies(13, 24, 31, 32)	35.27 U/L (95% CI: 27.37–43.16; I ² = 100%)
TBil level from 12 studies(1, 2, 13, 14, 19, 23, 24, 29, 31, 32)	11.16 μmol/L (95% CI: 9.14–13.18; I ² = 100%)
Albumin from 11 studies(1-3, 14, 15, 19, 22, 25, 31, 32, 34)	35.52 g/L (95% CI: 33.63–37.41; I ² = 100%)
PT from 11 studies(1, 2, 14, 15, 21, 23, 26, 29, 31-33)	11.27s (95% CI: 10.55–11.98; I ² = 100%)
LDH level from 11 studies(1-3, 16, 19, 20, 23, 25, 26, 31, 33)	252.99 U/L (95% CI: 225.51–280.48; I ² = 100%)
ALP level from 5 studies(1, 13, 14, 24, 31)	63.21 U/L (95% CI: 33.51–92.91; I ² = 100%)

Factors	Arms	Patients (N)	SMD	95%CI	I2(%)	P-value
ALT(1, 2, 11, 13-16, 19-26)	Mild	1528	-1.43	2.29 to -0.57	98%	0.001
	Severe	1743				
AST(1, 2, 11, 13-16, 19-25)	Mild	1350	-4.43	-2.29 to -0.57	98%	0.001
	Severe	1709				
GGT(13, 24)	Mild	283	-4.53	-5.36 to -3.72	69%	< 0.00001
	Severe	114				
TBil(1, 2, 11, 13, 14, 19, 23-26)	Mild	1270	-0.76	-1.29 to -0.22	96%	0.005
	Severe	1679				
Albumin(1, 2, 11, 14, 15, 19, 22, 25)	Mild	806	3.12	1.92 to 4.32	98%	< 0.00001
	Severe	1501				
PT(2, 11, 19, 21, 23, 25, 26)	Mild	651	-1.35	-3.27 to 0.58	99%	0.17
	Severe	249				
ALP(13, 14, 24)	Mild	575	-0.44	-1.67 to 0.79	98%	0.48
	Severe	881				
LDH(1, 2, 11, 16, 19, 20, 23, 25, 26)	Mild	777	-4.46	-5.98 to -2.93	98%	< 0.00001
	Severe	815				

4c. Liver function related indexes based on the outcome (Survivor Versus Non-Survivor) in COVID-19 patients.

Factors	Arms	Patients (N)	SMD	95%CI	I2(%)	P-value
ALT(3, 30-36)	Survivor	1087	-0.73	-1.38 to -0.08	97%	0.03
	Non-Survivor	570				
AST(30-36)	Survivor	950	-3.02	-4.55 to -1.49	99%	0.0001
	Non-Survivor	516				
GGT(31, 32)	Survivor	319	-0.74	-4.10 to 2.63	99%	0.67
	Non-Survivor	134				
TBil(29-32)	Survivor	421	-1.54	-3.23 to -0.15	98%	0.07
	Non-Survivor	234				
Albumin(3, 30-32, 34)	Survivor	574	2.47	0.07 to 4.88	88%	0.04
	Non-Survivor	275				
PT(3, 29, 31-33)	Survivor	750	-2.32	-3.95 to -0.69	99%	0.005
	Non-Survivor	285				
LDH(3, 30, 31, 33, 34)	Survivor	690	-4.84	-8.20 to -1.48	99%	0.005
	Non-Survivor	319				

4d. Pooled prevalence of abnormal liver function related indexes in COVID-19 patients.

Factors	Pooled results
ALT level from 7 studies(2, 3, 8, 13, 16, 28, 31)	39.5% (95% CI: 4.8–74.1; I ² = 100%)
AST level from 7 studies(2, 8, 13, 16, 19, 28, 31)	28.6% (95% CI: 21.1–36.1; I ² =91%)
TBil level from 3 studies(2, 8, 13)	26.5% (95% CI: 0.2–52.7; I ² = 99%)
Albumin level from 2 studies(2, 31)	66.8% (95% CI: 4.6–129; I ² = 100%)
PT from 3 studies(2, 3, 28)	8.3% (95% CI: 1.2–15.4; I ² = 90%)
LDH level from 6 studies(2, 3, 8, 16, 19, 31)	55.5% (95% CI: 26.7–84.4; I ² = 100%)

4e. Prevalence of abnormal liver function related indexes based on the severity (Mild versus Severe) in COVID-19 patients.

Factors	Arms	Patients (N)	ORs	95%CI	I2(%)	P-value
ALT(8, 13, 16, 28)	Mild	259	0.42	0.22 to 0.81	63%	0.009
	Severe	119				
AST(8, 11, 13, 16, 19, 28)	Mild	236	0.31	0.24 to 0.41	44%	< 0.00001
	Severe	115				
TBil(8, 13)	Mild	199	0.58	0.39 to 0.87	0%	0.008
	Severe	81				
LDH(8, 16, 19)	Mild	248	0.21	0.08 to 0.56	76%	0.002
	Severe	112				

4f. Prevalence of abnormal liver function related indexes based on the outcome (Survivor Versus Non-Survivor) in COVID-19

patients

Factors	Arms	Patients (N)	ORs	95%CI	I2(%)	P-value
ALT(3, 31)	Survivor	63	0.49	0.32 to 0.06	47%	0.001
	Non-Survivor	56				
LDH(3, 31)	Survivor	93	0.03	0.02 to 0.06	0%	< 0.00001
	Non-Survivor	146				

4g. Drugs used in the treatment of COVID-19 patients

Factors	Arms	Patients	ORs	95%CI	I2(%)	P-
		(N)				value
Lopinavir/ritonavir(10, 13, 37)	With liver injury	142	2.64	0.83 to 8.39	85%	0.10
	Without liver	282				
	injury					
Oseltamivir(10, 13)	With liver injury	37	1.17	0.32 to 4.27	82%	0.82
	Without liver	72				
	injury					
Antibiotics(10, 13, 37)	With liver injury	85	1.87	0.26 to	95%	0.53
	Without liver	85		13.45		
	injury					
Nonsteroidal anti-inflammatory drugs (NSAIDs)(10,	With liver injury	60	1.27	0.06 to	94%	0.88
13)	Without liver	89		26.89		
	injury					

3e. Prognosis of COVID- 19 patients with liver injury

Factors		Arms	Patients (N)	ORs/SMD	95%CI	I2(%)	P-value
Severity	/	With liver	130	OR: 2.57	1.25 to 5.26	62%	0.01

	injury Without liver	572	_			
Mortality	injury With liver	42	OR: 1.66	1.04 to 2.64	35%	0.03
wortanty	injury	-72	010. 1.00	1.04 10 2.04	3370	0.05
	Without liver injury	169				
Length of Hospital Stay	With liver injury	116	SMD: -0.61	2.37 to 1.15	98%	0.50
	Without liver injury	181				

ABBREVIATIONS: ALP- Alkaline phosphatase; ALT- Alanine aminotransferase; AST- Aspartate aminotransferase; GGT- Gammaglutamyltransferase; PT- Prothrombin time; TBil- Total bilirubin;LDH- Lactate dehydrogenase; ORs- Odds ratios; SMD-Standardised mean difference